Biogen wants you to know it's more than BAN2401

Biogen kept information on its closely watched Alzheimer's drug BAN2401 well-guarded during a Tuesday earnings call, choosing instead to focus on the durability of its multiple sclerosis portfolio and the growth of its muscular degeneration business.